Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?
Mikrobielle Diversität und Zusammensetzung im Darmmikrobiom von Patient:innen mit systemischem inflammatorischem Response-Syndrom: können Darmbakterien als potenzielle Biomarker zur Charakterisierung von Sepsis genutzt werden?
Frontiers in Cellular and Infection Microbiology · 22.08.2025 · 15
DOI: 10.3389/fcimb.2025.1622866 ↗Auf einen Blick
Bei 89 Stuhlproben unterschieden sich Sepsis- und Nicht-Sepsis-Patient:innen in der frühen Antibiotikatherapie im Darmmikrobiom. Später waren die Unterschiede nicht mehr signifikant.
Fragestellung
Unterscheiden sich Darmmikrobiota-Merkmale zwischen Sepsis- und Nicht-Sepsis-Patient:innen und könnten bakterielle Taxa zur Charakterisierung von Sepsis dienen?
Methode
89 Stuhlproben (51 Nicht-Sepsis, 38 Sepsis) wurden per 16S-rRNA-Amplikonsequenzierung analysiert; Stratifizierung nach früher und prolongierter Antibiotikatherapie sowie nach Beta-Laktam-Regimen.
Ergebnisse
In der frühen AT war die Alpha-Diversität bei Sepsis niedriger als bei Nicht-Sepsis (Shannon 2,48 vs. 3,0; p = 0,01). Die Beta-Diversität unterschied sich ebenfalls (PERMANOVA p = 0,005).
Schlussfolgerung der Autor:innen
Sepsis- und Nicht-Sepsis-Patient:innen zeigten in der frühen AT unterschiedliche Darmmikrobiota-Profile. Die Befunde deuten auf Dysbiose bei Sepsis und auf mögliche mikrobiombasierte Strategien hin.
Kernaussagen
- Frühe AT: niedrigere Alpha-Diversität bei Sepsis
- Frühe AT: Unterschiede in der Beta-Diversität
- Taxa-Verschiebungen: weniger Anaerobutyricum, mehr Holdemania/Klebsiella
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 22.08.2025. Verfasst von Rafaela Ramalho Guerra und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bacterial Resistance Research Laboratory (LABRESIS), Hospital de clínicas de Porto Alegre (HCPA), Experimental Research Center, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Sepsis, Systemic Inflammatory Response Syndrome, Gastrointestinal Microbiome, Bacteria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hospital de Clínicas de Porto Alegre.
Themen: Sepsis
Abstract (Originalsprache)
Background
Critically ill patients, including those with systemic inflammatory response syndrome (SIRS) and sepsis, frequently exhibit gut microbiota disruption due to physiological stress and broad-spectrum antimicrobial therapy (AT). Although antibiotics are essential for controlling infection, they can destabilize the gut microbiota and may contribute to poorer clinical outcomes. The characterization of the gut microbiota of these patients may inform microbiota-based interventions to mitigate antibiotic-induced dysbiosis.
Objective
This study aimed to identify key bacterial taxa that distinguish sepsis from non-sepsis patients.
Methods
A total of 89 stool samples (51 non-sepsis, 38 sepsis) were evaluated by amplicon sequencing the 16S rRNA gene to assess microbiota diversity and differential abundance. Samples were stratified by antibiotic exposure time: early AT (within 5th days of initiation) and prolonged AT (6th to 10th days). Additionally, patients were also grouped based on their AT: beta-lactam combined with other antimicrobial classes (BL-combined) and beta-lactam monotherapy (BL).
Results
During early AT, alpha diversity (Shannon index) was significantly lower in sepsis patients compared to non-sepsis patients (2.48 vs . 3.0, p = 0.01 ), whereas no significant difference was observed after prolonged treatment (2.65 vs . 2.89, p = 0.58 ). Beta diversity analysis (Aitchison distance) revealed significant differences between groups early AT (PERMANOVA, p = 0.005 ), but not in the later phase ( p = 0.54 ), suggesting that microbial communities converge over time. Early AT taxonomic profiling showed a decrease in Anaerobutyricum spp. and an increase in Holdemania spp. in the sepsis group. In the non-sepsis group, Veillonella spp. was impacted by time and beta-lactam combination. Turicibacter spp. showed a reduction in the prolonged AT sepsis group, while Klebsiella spp. was more abundant in the BL-combined sepsis patients.
Conclusions
Sepsis and non-sepsis patients showed distinct gut microbiota profiles in early AT. In sepsis, the loss of taxa involved in key metabolic functions, as short-chain fatty acid production, reflects dysbiosis and may contribute to worse outcomes. Prolonged antibiotic use may favor enteropathogen overgrowth and gut translocation. These findings highlight the potential of microbiota-based strategies to guide antimicrobial therapy and improve clinical outcomes in critically ill patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bacterial Resistance Research Laboratory (LABRESIS), Hospital de clínicas de Porto Alegre (HCPA), Experimental Research Center, Porto Alegre, Brazil.
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
- Bioinformatics Core, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
- Infectious Diseases Department, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
- Postgraduate Program in Medical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
- Department of Critical Care, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Förderung
- Hospital de Clínicas de Porto Alegre
Zitieren
APA
Ramalho Guerra, R., da Silva Fernandes, P., von Ameln Lovison, O., de Ross Forni, G., Silva de Oliveira, G., Viana, L. C., Castro Pereira, D., Latosinski Matos, W., Melo Silveira Moretti, M., Zempulski Volpato, F., Giordani, L., Orlandi Barth, P., Vieceli, T., Rodrigues Falci, D., Manozzo Boniatti, M., Barth, A. L., & Martins, A. F. (2025). Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1622866
Vancouver
Ramalho Guerra R, da Silva Fernandes P, von Ameln Lovison O, de Ross Forni G, Silva de Oliveira G, Viana LC, et al. Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1622866
BibTeX
@article{RamalhoGuerra2025,
author = {Ramalho Guerra, Rafaela and da Silva Fernandes, Patricia and von Ameln Lovison, Otávio and de Ross Forni, Giovanna and Silva de Oliveira, Gabriel and Viana, Luana Cristina and Castro Pereira, Dariane and Latosinski Matos, William and Melo Silveira Moretti, Miriane and Zempulski Volpato, Fabiana and Giordani, Luciana and Orlandi Barth, Patricia and Vieceli, Tarsila and Rodrigues Falci, Diego and Manozzo Boniatti, Márcio and Barth, Afonso Luís and Martins, Andreza Francisco},
title = {Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
volume = {15},
doi = {10.3389/fcimb.2025.1622866}
}
EUVIMED